MC4R raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-03. Anything still debated is marked as such rather than presented as settled.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
== Manufacturing == During the production of the topical cream formulation, the first step is to dissolve excipients in the phase in which they are soluble. The initial mixing temperature of both phases should be high enough to ensure intimate liquid mixing and avoid premature solidification of the oily phase by the colder water. The aqueous phase should be warmed to a temperature slightly higher than the oily phase. The second step is the mixing of both the aqueous phase and the oily phase by adding either the dispersed phase to the continuous phase, or the continuous phase to the dispersed phase. The effect of the addition order and the addition rate on the drug product quality should be evaluated during process development. The third step is the introduction of the active substances into the mixture. Some active pharmaceutical ingredients can be dissolved at high temperatures but recrystallize during the cooling stage after mixing. To prevent recrystallization, the active substances can be carried to the cooled down cream base via a powder induction system or through slurry addition. The active substances are simultaneously mixed into the cream base. The last step is the homogenization stage. Agitators, mechanical mixers, rotor stators, homogenizers, or ultrasonic devices can be employed to ensure uniform excipient dispersion and droplet size reduction. Critical variables of the homogenization equipment include time, temperature, and mechanical energy. Critical parameters must be controlled to produce products of consistent quality.
== History == During the 1980s, Jean-Pierre Raufman worked as a postdoctoral researcher at the National Institutes of Health for John Pisano, a biochemist who specialized in collecting venom from various animals and looking for novel substances that could affect human physiology. In the course of this work, Raufman focused on the Gila monster, because he was curious about its practice of eating once or twice per year. He reported that Gila monster venom had biologically active molecules that provoked inflammation of the pancreas in test animals. In 1992, after learning of Raufman's findings, John Eng of the Veterans Administration Medical Center in New York City used radioimmunoassay to isolate a novel substance from Gila monster venom. The new substance, which Eng called exendin-4, was similar to GLP-1 in that it reduced blood glucose in diabetic mice, but exendin-4 had a much longer half-life than GLP-1, whose extremely short half-life had defeated earlier attempts to turn it into a drug. Eng filed a patent application for exendin-4 in 1993. He then spent three years searching for a pharmaceutical industry partner interested in commercializing exendin-4. In 1996, Amylin Pharmaceuticals licensed Eng's patent and created a synthetic version of exendin-4 called exenatide. In 2002, Eli Lilly and Company partnered with Amylin to develop exenatide and secure approval to market the drug. Exenatide's 2005 approval by the U.S.
=== Television === The condition was brought to public attention in 2004 in the UK through the Channel 4 documentary The Boy Whose Skin Fell Off, chronicling the life and death of Jonny Kennedy, an Englishman with EB. In the United States, HBO ran a documentary, My Flesh and Blood, in 2003. Additionally, the film Butterfly Girl follows Abigail Evans with the disease. In Canada, The Sports Network's award-winning documentary on Jonathan Pitre led to extensive coverage on the boy's disease, treatment, and death.
Mash et al. (2000), using lower oral doses (10–12 mg/kg) in 27 patients, demonstrated significantly lower objective opiate withdrawal scores in heroin addicts 36 hours after treatment, with self-reports of decreased cocaine and opiate craving and alleviated depression symptoms. Many of these effects appeared sustainable over a one-month post-discharge follow-up.
==== Remittance tax ==== Effective January 1, 2026, the law establishes a 1% excise tax on certain electronic transfers of funds from the United States to a foreign country. The tax is on the electronic transfer of funds from an individual located in any U.S. state, U.S. territory, or the District of Columbia to a recipient in a foreign country for personal, family, or household purposes. The excise tax is assessed on electronic transfers sent using cash, money orders, cashier's checks, prepaid card reloads, wire transfers, online bill payments, and similar methods. The excise tax is assessed on the amount transferred and not on any fees that the sending institution charges the sender to complete the transfer. The excise tax is supposed to be paid by the sender of the remittance; the transfer provider must pay the excise tax if the sender does not. A transfer to a U.S. military base located in a foreign country are considered to be received in the United States and is not subject to the remittance tax. Additionally, transfers of $15 or less are not subject to the remittance tax. Certain transfers are exempt, such as those from financial accounts held at institutions subject to the Bank Secrecy Act, such as U.S. banks, U.S. credit unions, U.S. investment companies, and certain U.S. branches of foreign banks; transfers paid with a U.S.-issued debit or credit card; and transfers of cryptocurrency.
Sources: en.wikipedia.org
==== Plans to sell TikTok's US operations ==== Since at least 2020, following calls to ban TikTok in the country, the Committee on Foreign Investment in the United States (CFIUS) has been investigating the company's 2017 merger with Musical.ly but has not finalized any of its negotiations with TikTok, such as the Project Texas proposal, waiting instead for Congress to act. In January 2025, Chinese officials began preliminary talks about potentially selling TikTok's US operations to Elon Musk if the app faced an impending ban due to national security concerns. While Beijing preferred TikTok remain under ByteDance's control, the sale could happen through a competitive process or with US government involvement. One possibility involved Musk's platform, X, taking over TikTok's US business. The move came ahead of a Supreme Court case that upheld the constitutionality of a law that would force a sale or ban of TikTok in the US by 19 January 2025, due to national security concerns regarding its ties to China. Other potential buyers included Project Liberty's "The People's Bid For TikTok" consortium of Frank McCourt with Kevin O'Leary, Steven Mnuchin, and Bobby Kotick, and an investor consortium led by Employer.com founder Jesse Tinsley that included Roblox CEO David Baszucki and YouTuber MrBeast and claimed to have secured over US$20 billion in commitments. The seriousness of these potential buyers was unclear. The day before the impending ban, California-based conversational search engine company Perplexity AI submitted a bid for a merger with TikTok US.
Pd complexes of XPhos catalyze the amination and amidation of arylsulfonates and aryl halides. XPhos has also been used in the Pd-catalyzed borylation of aryl and heteroaryl chlorides Modified versions of XPhos, he more hindered t-BuXPhos and Me4tButylXPhos, have been employed in the formation of diaryl ethers. Incorporation of a sulfonate group at the 4-position allows this ligand to be used for Sonogashira couplings in aqueous biphasic solvents.
=== Mouse === Mice have no less than 7 FPR receptors encoded by 7 genes that localize to chromosome 17A3.2 in the following order: Fpr1, Fpr-rs2 (or fpr2), Fpr-rs1 (or LXA4R), Fpr-rs4, Fpr-rs7, Fpr-rs7, Fpr-rs6, and Fpr-rs3; this locus also contains Pseudogenes ψFpr-rs2 and ψFpr-rs3 (or ψFpr-rs5) which lie just after Fpr-rs2 and Fpr-rs1, respectively. The 7 mouse FPR receptors have ≥50% amino acid sequence identity with each other as well as with the three human FPR receptors. Fpr2 and mFpr-rs1 bind with high affinity and respond to lipoxins but have little or no affinity for, and responsiveness to, formyl peptides; they thereby share key properties with human FPR2;
=== Pitfalls === Notably, attempts to surgically remove bone in a FOP patient may result in explosive growth of new bone. While undergoing anesthesia, people with FOP may encounter difficulties with intubation, restrictive pulmonary disease, and changes in the electrical conduction system of the heart. Activities that increase the risk of falling or soft tissue injury should be avoided, as even minor trauma may provoke heterotopic ossification. Intramuscular injections, including immunizations, should likewise be avoided in individuals with FOP, as these can also trigger ossification. Currently, surgery is not usually recommended for people with FOP as it can incite rapid bone formation at incision sites or where sutures have been applied to muscle or connective tissue. Life-saving surgery may be considered; however, developing a surgical plan with input from a FOP specialist may be considered best practice. Surgical release of joint contractures is generally unsuccessful and risks new, trauma-induced heterotopic ossification.
Their mass-to-charge ratio is proportional to their time of flight (TOF) in the drift tube and can be calculated accordingly. Coupling ESI with capillary LC can separate peptides from protein digests, while obtaining their molecular masses at the same time. Capillary electrophoresis coupled with ESI-MS is another technique; however, it works best when analyzing small amounts of proteins.
Sources: en.wikipedia.org
China provided a transcript of a 26 April press conference, indicating that an invitation to FDA investigators had been sent on 23 April but making no mention of banning melamine usage. On 3 May 2007, Chinese authorities detained Mao Lijun, general manager of the Xuzhou Anying Biologic Technology Development, one of the companies accused of exporting contaminated protein, on unspecified charges. On 29 May 2007, in actions not linked directly to the protein export scandal, Zheng Xiaoyu (郑筱萸), the former head of China's State Food and Drug Administration (SFDA), had been convicted of personally approving unproven and unsafe medicines after taking bribes from eight pharmaceutical companies totaling more than 6.49 million RMB (approximately 850,000 US dollars). These fraudulent approvals were estimated to have resulted in hundreds of patient deaths; consequently, Zheng was sentenced to death. It was also discovered during his eight years as head of the SFDA, Zheng had personally ordered the approval of more than 150,000 new medicines; by contrast, the U.S. FDA approves approximately 140 new medications per year. Most of those 150,000 medicines were manufactured by the eight pharmaceutical companies that bribed Zheng; one such unsafe medication, produced by the now-defunct Anhui Hua Yuan (华源) Company, resulted in 14 patient deaths and hundreds becoming permanently disabled. Zheng's former deputy was also convicted as an accomplice and given a two-year delayed death sentence.
Forensic chemists' analysis can provide leads for investigators, and they can confirm or refute their suspicions. The identification of the various substances found at the scene can tell investigators what to look for during their search. During fire investigations, forensic chemists can determine if an accelerant such as gasoline or kerosene was used; if so, this suggests that the fire was intentionally set. Forensic chemists can also narrow down the suspect list to people who would have access to the substance used in a crime. For example, in explosive investigations, the identification of RDX or C-4 would indicate a military connection as those substances are military grade explosives. On the other hand, the identification of TNT would create a wider suspect list, since it is used by demolition companies as well as in the military. During poisoning investigations, the detection of specific poisons can give detectives an idea of what to look for when they are interviewing potential suspects. For example, an investigation that involves ricin would tell investigators to look for ricin's precursors, the seeds of the castor oil plant. Forensic chemists also help to confirm or refute investigators' suspicions in drug or alcohol cases. The instruments used by forensic chemists can detect minute quantities, and accurate measurement can be important in crimes such as driving under the influence as there are specific blood alcohol content cutoffs where penalties begin or increase.
Originally planned for the second revolution, the astronauts postponed the EVA until the third after McDivitt decided that White, following the stress of the launch and the failed rendezvous, looked tired and hot. After a rest, the pair finished performing the checklist for the EVA. Flying over Carnarvon, Australia, they began to depressurize the cabin. Over Hawaii, White pulled the handle to open his hatch, but the latches failed to move. Fortunately, McDivitt knew what the problem was, because the hatch had failed to close in a vacuum chamber test on the ground, after which McDivitt worked with a technician to see what the cause was. A spring, which forced gears to engage in the mechanism, had failed to compress, and McDivitt got to see how the mechanism worked. In flight, he was able to help White get it open and thought that he could get it to latch again. There were communication problems during the spacewalk. Gemini spacecraft were the first to use a voice-operated switch (known as VOX) on the astronaut's microphones, but McDivitt soon realized that his VOX circuit was not working properly; he could only hear the Capsule Communicator (CAPCOM) in the push-to-talk setting, but not on VOX (though both astronauts could be heard by each other and the ground). Plus, while outside the spacecraft, White was unable to receive transmissions from the ground and had to have all messages relayed through McDivitt.
== Diagnosis == Fasting Insulin levels in blood may be measured as this can be elevated in the presence of normal glucose. Diagnosis is often made by checking normal levels of glucose that exceed 1.7 mmol/L (30 mg/dL) when 1 mg of glucagon is administered IM or IV. In addition, urine samples or blood samples are also used to check levels of ketones and low free fatty acids. After diagnosis, most people are required to continue regular check ups for evaluations.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.